You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Dow
Express Scripts
McKesson
AstraZeneca

Last Updated: February 24, 2020

DrugPatentWatch Database Preview

ODOMZO Drug Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which patents cover Odomzo, and what generic alternatives are available?

Odomzo is a drug marketed by Sun Pharma Global and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and nine patent family members in forty-eight countries.

The generic ingredient in ODOMZO is sonidegib phosphate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sonidegib phosphate profile page.

US ANDA Litigation and Generic Entry Outlook for Odomzo

Odomzo was eligible for patent challenges on July 24, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 15, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for ODOMZO
Drug patent expirations by year for ODOMZO
Drug Prices for ODOMZO

See drug prices for ODOMZO

Generic Entry Opportunity Date for ODOMZO
Generic Entry Date for ODOMZO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ODOMZO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Melanoma Institute AustraliaPhase 2
National Cancer Institute (NCI)N/A
Anne ChangN/A

See all ODOMZO clinical trials

Pharmacology for ODOMZO
Synonyms for ODOMZO
(1,1'-Biphenyl)-3-carboxamide, N-(6-((2R,6S)-2,6-dimethyl-4-morpholinyl)-3-pyridinyl)-2-methyl-4'-(trifluoromethoxy)-, rel-, phosphate (1:2)
1218778-77-8
3888AH
AKOS015994565
AOB87343
BCP11860
C26H26F3N3O3.2H3O4P
CHEBI:90864
CHEMBL3137317
CS-1175
D10729
DTXSID90669468
Erismodegib Diphosphate
Erismodegib Diphosphate, NVP-LDE225 (diphosphate salt)
EX-A1556
FE-0016
HY-16582
KS-00002WSZ
LDE-225 Diphosphate
LDE225 (Diphosphate)
LDE225 Diphosphate
MolPort-009-194-128
N-(6-((2R,6S)-2,6-Dimethylmorpholino)pyridin-3-yl)-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide bis(phosphate)
NVP-LDE225 Diphosphate
NVP-LDE225 Diphosphate salt
Odomzo (TN)
Phosphoric acid--N-{6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide (2/1)
rel-N-{6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl}-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide bis(phosphate)
SB16677
sonidegib bisphosphate
sonidegib diphosphate
Sonidegib phosphate
Sonidegib phosphate (USAN)
Sonidegib phosphate [USAN:INN]
UNII-W421AI34UW
W-6021
W421AI34UW

US Patents and Regulatory Information for ODOMZO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharma Global ODOMZO sonidegib phosphate CAPSULE;ORAL 205266-001 Jul 24, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Sun Pharma Global ODOMZO sonidegib phosphate CAPSULE;ORAL 205266-001 Jul 24, 2015 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Sun Pharma Global ODOMZO sonidegib phosphate CAPSULE;ORAL 205266-001 Jul 24, 2015 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ODOMZO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2021328 PA2015051,C2021328 Lithuania   Start Trial PRODUCT NAME: SONIDEGIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, HIDRATAS ARBA SOLVATAS; REGISTRATION NO/DATE: EU/1/15/1030 20150818
2021328 1590062-4 Sweden   Start Trial PRODUCT NAME: SONIDEGIB OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF; REG. NO/DATE: EU/1/15/1030 20150818
2021328 255 5026-2015 Slovakia   Start Trial FORMER OWNER: NOVARTIS AG, CH
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Johnson and Johnson
Dow
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.